Retinazone Inhibits Certain Blood-Borne Human Viruses Including Ebola Virus Zaire

@article{Kesel2014RetinazoneIC,
  title={Retinazone Inhibits Certain Blood-Borne Human Viruses Including Ebola Virus Zaire},
  author={Andreas Johannes Kesel and Zhuhui Huang and Michael G. Murray and Mark N Prichard and Laura Caboni and Daniel K Nevin and Darren Fayne and David G. Lloyd and Mervi A. Detorio and Raymond F. Schinazi},
  journal={Antiviral Chemistry and Chemotherapy},
  year={2014},
  volume={23},
  pages={197 - 215}
}
Background: Human HBV and HIV integrate their retro-transcribed DNA proviruses into the human host genome. Existing antiretroviral drug regimens fail to directly target these intrachromosomal xenogenomes, leading to persistence of viral genetic information. Retinazone (RTZ) constitutes a novel vitamin A-derived (retinoid) thiosemicarbazone derivative with broad-spectrum antiviral activity versus HIV, HCV, varicella-zoster virus and cytomegalovirus. Methods: The in vitro inhibitory action of RTZ… Expand
A standardized approach to the evaluation of antivirals against DNA viruses: Polyomaviruses and lymphotropic herpesviruses
TLDR
The assessment of antiviral activity of a set of nucleoside analogs against BK polyomavirus, JC polyomvirus, Epstein‐Barr virus, human herpesvirus 6B, and human herpesVirus 8 is described in an automated 384‐well format and qPCR assays to measure the accumulation of viral DNA. Expand
Mega doses of retinol: A possible immunomodulation in Covid‐19 illness in resource‐limited settings
TLDR
The current review explores the possibility of mega dose vitamin A as an affordable adjunct therapy for Covid‐19 illness with minimal reversible side effects and insight is provided into the effect of vitamin A on ACE‐2 expression in the respiratory tract and its association with the prognosis of Covid-19 patients. Expand
Small molecule inhibitors of ebola virus infection.
TLDR
The state-of-the-art in small molecule inhibitors of ebola virus infection are detailed, with >60 examples, including approved drugs, compounds currently in clinical trials, and more exploratory leads, and summarize the associated in vitro and in vivo evidence for their effectiveness. Expand
Ebola Virus Disease: Biology, Diagnosis, Treatment and Prevention of Epidemics
TLDR
The properties of the Ebola virus and EVD, the ongoing attempts to develop diagnostics, vaccines and medicines for prevention and cure of EVD and the supportive care that saves some EVD patients are described. Expand
Development of Small‐Molecule Antivirals for Ebola
  • Z. Janeba
  • Medicine
  • Medicinal research reviews
  • 2015
TLDR
Attempts in identification, evaluation, and development of small‐molecule candidates for treatment of Ebola viral disease are summarized, including the most promising experimental drugs brincidofovir (CMX001), BCX4430, and favipiravir (T‐705). Expand
PT150 is a modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2
TLDR
It is hypothesized that anti-SARS-CoV-2 activity depends in part on this AR downregulation through diminished TMPRSS2 expression and modulation of ACE2 activity, and an additive role for its potent immunomodulatory effects through systemic antagonism of cortisol is postulated. Expand
Repurposing drugs for treatment of SARS-CoV-2 infection: computational design insights into mechanisms of action
TLDR
The results from this study may help to accelerate drug development against COVID-19 and the hit compounds should be progressed through further in vitro and in vivo studies on SARS-CoV-2. Expand
Clinical stage molecule PT150 is a modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2.
TLDR
It is hypothesized that anti-SARS-CoV-2 activity depends in part on this AR downregulation through diminished TMPRSS2 expression and modulation of ACE2 activity, and an additive role for its potent immunomodulatory effects through systemic antagonism of cortisol is postulated. Expand
Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection
TLDR
A repurposing screen of 6438 drugs from DrugBank using a simple theoretical criterion for fast virtual screening of molecular libraries for candidate inhibitors of Ebola virus infection selected 267 approved and 382 experimental drugs as candidates for treatment of EVD. Expand
Vitamin A Supplementation Was Associated with Reduced Mortality in Patients with Ebola Virus Disease during the West African Outbreak.
TLDR
Early vitamin A supplementation was associated with reduced mortality in patients with EVD, and should be further studied and considered for use in future epidemics. Expand
...
1
2
...

References

SHOWING 1-10 OF 82 REFERENCES
Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative.
  • A. J. Kesel
  • Chemistry, Medicine
  • European journal of medicinal chemistry
  • 2011
TLDR
Results indicate that thiosemicarbazone derivatives are appropriate lead structures to be evaluated in targeted antiviral therapies for hepatitis C (STAT-C), and that the vitamin A-related thiOSEmicarbzone derivative 12 emerges as a broad-spectrum antiviral agent, co-suppressing the multiplication of important RNA and DNA viruses. Expand
NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon
TLDR
Promising in vitro data warrant clinical investigation of NIM811, an inhibitor of novel mechanism, for the treatment of hepatitis C, since it binds to cyclophilins with higher affinity than cyclosporine but is devoid of the significant immunosuppressive activity associated with cyclospora. Expand
Effective inhibition of HCMV UL49 gene expression and viral replication by oligonucleotide external guide sequences and RNase P
TLDR
Results indicated that UL49 gene was essential for replication of HCMV, and provided evidence that exogenous administration of a DNA-based EGS can be used as a potential therapeutic approach for inhibiting gene expression and replication of a human virus. Expand
ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
TLDR
Antiviral assays revealed that ASP2151, unlike other known HSV helicase-primase inhibitors, exerts equipotent activity against VZV, HSv-1 and HSV-2 through prevention of viral DNA replication. Expand
Antiviral Activity of a Small-Molecule Inhibitor of Filovirus Infection
TLDR
In a murine model of ZEBOV infection, delivery of FGI-103 reduces viremia and the viral burden in kidney, liver, and spleen tissues and is associated with subdued and delayed proinflammatory cytokine responses and tissue pathology, which identify a promising antiviral therapeutic candidate for the treatment of filovirus infections. Expand
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation
TLDR
Evidence is described that Vif binds APOBEC3G and induces its rapid degradation, thus eliminating it from cells and preventing its incorporation into HIV-1 virions, providing promising approaches for drug discovery. Expand
Small molecule inhibitors reveal Niemann-Pick C1 is essential for ebolavirus infection
TLDR
The identification of a novel benzylpiperazine adamantane diamide-derived compound that inhibits EboV infection is reported and it is found that NPC1 is essential for infection, that it binds to the virus glycoprotein (GP), and that antiviral compounds interfere with GP binding to NPC1. Expand
Cyclopropavir Inhibits the Normal Function of the Human Cytomegalovirus UL97 Kinase
TLDR
It is concluded that the mechanism of action of CPV against CMV is complex and involves both the inhibition of DNA synthesis and the inhibited of the normal activity of the UL97 kinase. Expand
Comparative Activities of Lipid Esters of Cidofovir and Cyclic Cidofovir against Replication of Herpesviruses In Vitro
TLDR
Results indicate that the lipid ester analogs of CDV are considerably more active than CDV itself against HSV, VZV, CMV, EBV, HHV-6, andHHV-8 in vitro, suggesting that they may have potential for the treatment of infections caused by a variety of herpesviruses. Expand
Curing HIV: Pharmacologic approaches to target HIV-1 latency.
TLDR
The molecular targets that might be exploited to induce HIV-1 expression, remove epigenetic restrictions, or enhance effective transcription are identified and the potential pharmacologic approaches toward targeting viral persistence in different cellular and anatomical reservoirs are discussed. Expand
...
1
2
3
4
5
...